Virtual Network's Login.
ESH Gold Institutional Partner
ESH Gold Institutional Partner
ESH Gold Institutional Partner
ESH Gold Institutional Partner
Over the past few years there has been a flood of new insights into the classification,pathogenesis and management of the myeloproliferative neoplasms. This meeting is essentially a workshop with an audience. It brings together scientists and clinicians with new data on the cellular and molecular biology of these disorders as well as their diagnosis and treatment.
|
Thursday, September 30, 2010 |
||
| Session I - Chair: T. Green | ||
| 17h30 | Welcome | T. Green (Cambridge, UK) |
| 17h35 | "TK inhibitors - lessons from CML for the MPNs" | J. Goldman (London) |
| 18h00 | Recombinant interferon alpha may retard progression of early primary myelofibrosis (PM) by reducing splenetically and by changing marrow morphology: results in 18 patients | R. Silver (New York) |
| 18h25 | Molecular basis of refractory anemia with ringed sideroblasts and marked thrombocytosis | M. Cazzola (Pavia) |
| 18h50 | The genomics of the myeloproliferative disorders | P. Campbell (Cambridge, UK) |
| 19h15 | Clonal evolution of MPN | R. Skoda (Basel) |
| 19h40 |
Finish |
|
| 20h00 | Cocktails and Dinner | |
|
Friday, October 1, 2010 |
||
| Session II - Chair: T. Barbui | ||
| 08h30 | Stem cell trafficking in primary myelofibrosis |
R. Hoffman (New York) |
| 08h55 | NF-E2 overexpression in vivo: a murine model of myeloproliferative disorders | H.L. Pahl (Freiburg) |
| 09h20 | Derangement of endotheliopoiesis in myeloproliferative neoplasms | G. Barosi (Pavia) |
| 09h45 | Modeling the human 8p11-myeloproliferative neoplasms syndrome in immuno-deficient mice | Helena Agestarm (Lund) |
| 10h00 | The myeloproliferative neoplasm-associated JAK2 V617F kinase is not endosomally sorted by SOCS3 | Joanne Elliott ( Belfast) |
| 10h15 |
TEA |
|
| 10h45 | Molecular pathogenesis of the myeloproliferative neoplasms |
T. Green (Cambridge, UK) |
| 11h10 | Genetic instability in myeloproliferative disorders |
W. Vainchenker (Paris) |
| 11h35 | MicroRNAs abnormalities in the myeloproliferative neoplasms | A. Vannucchi (Florence) |
| 12h00 | The Dominant Negative b Isoform of the Glucocorticoid Receptor is Uniquely Expressed in Erythoid Cells Expanded from Patients with Polycythemia Vera | Anna Rita Migliaccio |
| 12h15 | Lnk contrains Myeloproliferative Disease (MPD) Development | Wei Tong (Philadelphia) |
| 12h30 | LUNCH & POSTERS | |
| Session III - Chair: W. Vainchenker | ||
| 17h45 | An update on INCB018424, an oral JAK1/2 inhibitor, as therapy for myelofibrosis |
S. Verstovsek (MD Anderson, USA) |
| 18h10 | Biomarkers of inflammation and thrombosis in myeloproliferative neoplasms | T. Barbui (Bergamo) |
| 18h35 | Jak2 V617F mutation in PV, is that the whole story? |
J. Prchal (Utah) |
| 19h00 | Signalling pathways in myeloproliferative disorders |
M.-F. McMullin (Belfast) |
| 19h25 | Finish | |
| 20h00 | Dinner | |
|
Saturday, October 2, 2010 |
||
| Session IV - Chair: H. Pahl | ||
| 08h30 | Phenotype and genotype in the chronic myeloproliferative disorders | J. Spivak (Baltimore) |
| 08h55 | S. Constantinescu (Brussels) | |
| 09h20 | New genes, new drugs, new data about old drugs: time to change MPD management? |
J.-J. Kiladjian (Paris) |
| 09h45 | Competitive potential of JAK2-V617F Stem Cells | Pontus Lundberg (Basel) |
| 10h00 | JAK2 V617F induced TNF resistance as a mechanism of clonal expansion in myeloproliferative neoplasm | Angela Fleischman (Portland) |
| 10h15 |
TEA |
|
| 10h45 | Molecular pathogenesis and therapy of essential thrombocythemia and primary myelofibrosis | R. Levine (Boston) |
| 11h10 | New prognositic models to predict prognosis in MPN | F. Passamonti (Pavia) |
| 11h35 | Deciphering the genetic complexity of myeloproliferative neoplasms | R. Kralovics (Vienna) |
| 12h00 | STAT5A over-expression induces hematopoietic exhaustion not only in transduced hematopoietic stem cells but also to non-transduced normal hematopoietic stem cells of primary myelofibrosis mouse | Skin Kaneko (Tokyo) |
| 12h15 | A phase II trial with RAD001 in myelofibrosis: results of an ancillary biological protocol | Paola Guglielmelli (Florence) |
| 12h30 | LUNCH & POSTERS | |
| Session V - Chair: R. Skoda | ||
| 14h00 |
Comparing the impact of current and new therapies on patients with myelofibrosis |
R. Mesa (Mayo Clinic, USA) |
| 14h25 | Function of TET2 in normal and malignant hematopoiesis | O. Bernard (Paris) |
| 14h50 | tbc | |
| 15h00 | Mutations associated with acquired uniparental disomy in MPN | N. Cross (Salisbury, UK) |
| 15h15 | Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukemia | V. Najfeld (New York) |
| 15h30 | Implication of the hemangioblast in the pathogenesis of myelofibrosis | I. Triviai (Hamburg) |
| 15h45 |
TEA |
|
| 16h15 |
Animal models of MPN |
J.-L. Villeval (Paris) |
| 16h40 | Intracellular signaling patterns correlate with cellular and disease phenotype in human myeloproliferative neoplasms |
B. Huntly (Cambridge) |
| 17h05 |
Mutations associated with acquired uniparental disomy in MPN |
N. Cross (Southampton, UK) |
| 17h30 | MANNED POSTER SESSION WITH REFRESHMENTS | |
| 19h00 |
Finish |
|
| 20h00 |
Conference Dinner |
|
Grande Real Santa Eulália
Praia de Santa Eulália
PO Box 2445 Albufeira
